Abstract
The phytochemical resveratrol has been reported to induce NQO1, an enzyme involved in detoxification reactions, by as yet undetermined mechanisms. Using K562 cells as a model, we showed that 25-50 μM resveratrol increased NQO1 that peaked at 24-48 h. A 2.5-fold rise in NQO1 protein levels was accompanied by a comparable elevation in mRNA copy number and a 3- to 5-fold increase in NQO1 enzymatic activity. Fluorescent microscopic analysis in combination with transfection experiments with plasmids harboring different segments of the 5-flanking region of NQO1 gene linked to a reporter provided evidence that the modulation of NQO1 gene expression by resveratrol involved the antioxidant response element ARE, accompanied by an increase in the state of phosphorylation of transcription factor Nrf2 and its re-distribution to the nucleus. This change in cellular localization of Nrf2 may be linked to resveratrol-elicited disruption of the Nrf2-Keap1 complex in the cytosol, followed by the translocation of Nrf2 to the nucleus where it locates the ARE-containing 5-promoter region of NQO1 leading to its transcriptional activation.
Keywords: response element ARE, antioxidant, transcriptional factor Nrf2, transcriptional control, K562 cells, quinone reductase 1, Resveratrol
Medicinal Chemistry
Title: Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2
Volume: 2 Issue: 3
Author(s): Joseph M. Wu, Tze-chen Hsieh, Xiaohua Lu and Zhirong Wang
Affiliation:
Keywords: response element ARE, antioxidant, transcriptional factor Nrf2, transcriptional control, K562 cells, quinone reductase 1, Resveratrol
Abstract: The phytochemical resveratrol has been reported to induce NQO1, an enzyme involved in detoxification reactions, by as yet undetermined mechanisms. Using K562 cells as a model, we showed that 25-50 μM resveratrol increased NQO1 that peaked at 24-48 h. A 2.5-fold rise in NQO1 protein levels was accompanied by a comparable elevation in mRNA copy number and a 3- to 5-fold increase in NQO1 enzymatic activity. Fluorescent microscopic analysis in combination with transfection experiments with plasmids harboring different segments of the 5-flanking region of NQO1 gene linked to a reporter provided evidence that the modulation of NQO1 gene expression by resveratrol involved the antioxidant response element ARE, accompanied by an increase in the state of phosphorylation of transcription factor Nrf2 and its re-distribution to the nucleus. This change in cellular localization of Nrf2 may be linked to resveratrol-elicited disruption of the Nrf2-Keap1 complex in the cytosol, followed by the translocation of Nrf2 to the nucleus where it locates the ARE-containing 5-promoter region of NQO1 leading to its transcriptional activation.
Export Options
About this article
Cite this article as:
Wu M. Joseph, Hsieh Tze-chen, Lu Xiaohua and Wang Zhirong, Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2, Medicinal Chemistry 2006; 2 (3) . https://dx.doi.org/10.2174/157340606776930709
DOI https://dx.doi.org/10.2174/157340606776930709 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Odontogenic Infections in the Etiology of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine Immunomodulatory Effect of Probiotic Bacteria
Recent Patents on Inflammation & Allergy Drug Discovery Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Hydrogels in Tissue Engineering: Scope and Applications
Current Pharmaceutical Biotechnology Protective Effect of Annurca Apple Extract Against Oxidative Damage in Human Erythrocytes
Current Nutrition & Food Science Meet the Editorial Board
Current Vascular Pharmacology Statistically Designed Extraction of Herbs Using Ultrasound Waves: A Review
Current Pharmaceutical Design Relationship between SNP rs1764391 and Susceptibility, Risk Factors, Gene-environment Interactions of Acute Myocardial Infarction in Guangxi Han Chinese Population
Current Pharmaceutical Biotechnology Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design